resum overweight
resum coverag ow pt follow complet
acquisit allergan view humira eros
fear overli discount prospect
underappreci earn multipl call
overweight invest thesi expect share outperform
compani deliv financi upsid make pipelin progress driver
off-set humira overhang believ current
valuat overli discount pessim compani humira cliff lack
new blockbust pipelin candid project result slightli
consensu new growth driver offset humira downsid
ep higher despit expect launch seven humira
biosimilar above-industri growth abbvi
face fewer gener risk mid-lat decad peer
anticip total return next year pt repres
potenti upsid plu offer dividend yield pt
ep note current trade ep
pt multipl histor rang
mean exhibit note pt repres trough
ep expect multipl expand come year think
could trade earli year trough ep multipl
low doubl digit higher forward growth trajectori beyond
encourag make assumpt abl return
growth us humira sale declin ultim trough
multipl depend upon degre pipelin success growth
expect section gentlest patent cliff post-humira
acquisit allergan add new growth franchis help blunt
neg impact us biosimilar allergan deal creat
diversifi compani better posit navig humira pressur
refer exhibit see allergan new growth driver would help
blunt humira eros particular acquir durabl growth asset
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
lead aesthet neurosci gastrointestin portfolio addit
deal provid scale profit growth platform ex-humira
well benefit mitig us humira loe loss exclus
high confid manag team led chairman ceo
gonzalez integr allergan given manag track record execut
debat stock perform us humira set roll
eye us humira given outsiz revenu contribut estimate
global compani sale anticip launch nine
biosimilar version bear argu stock could face pressur
cliff approach argu risk well understood expect
effect navig humira eros project us humira sale
follow declin
even though consensu
humira product revenu upsid off-set humira
downsid yield total compani result consensu expect new
product growth driver includ autoimmun diseas drug skyrizi rinvoq
exceed long-term consensu expect roll new diseas
indic higher-dur revenu stream valuabl
assign higher multipl humira view
pipelin surpris upsid think market could start price
bull case valuat street current low
expect pipelin given lack blockbust late-stag
candid result see potenti expect rise early-
stage pipelin readout occur number oncolog asset includ
antagonist protein gener data next year
addit high-risk high-reward candid diseas area offer
platform ph data expect come week alzheim candid ant-tau
expect gener ph data pipelin section
could wrong growth driver could miss sale could fall
short due impact rise unemploy net sale allergan
acquisit could disappoint pipelin failur could occur humira biosimilar
pressur could wors project
tabl content
pt base base case ep price-to-earnings multipl peer mean
due product humira eros
prospect multipl expans potenti
project nancial result
consensu next year
pipelin expect low offer
like pursu extern
transact enhanc pipelin
view descript risk reward theme
rise unemploy impact us
downsid key franchis miss
price pressur major growth driver
skyrizi rinvoq fall
short allergan revenu cost synergi
disappoint epsar
newsow pipelin disappoint
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario
price either three-month one-year time view explan option probabl methodolog
financi result pipelin
surpris upsid sale cost
forecast high-risk/high-reward
newsow upward revisionsto long-term
financi result consensu
expect price-to-earnings expand
includ key product growth
pipelin candid expect
posit pipelin develop near-term
balanc long-term humira biosimilar
threat includ risk us biosimilar
interchang bi candid
financi result rel expect
china india
view explan region hierarchi
research highest favor quintil
synergi upsid posit pipelin surpris
result expect pipelin
competit threat disappoint
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
may close acquisit allergan cash stock
transact equiti valu base close stock price
may allergan sharehold receiv share
cash share sharehold new compani
allergan sharehold also assum net debt make
transact reduc relianc humira offer immedi financi
strateg valu combin allergan diversifi on-market product portfolio
abbvi growth platform deep expertis commerci strength
intern footprint creat lead biopharmaceut compani
approxim billion combin revenu combin compani lead
franchis immunolog hematolog oncolog medic aesthet neurosci
import franchis includ gastrointestin women health eye care
valu creation opportun includ pre-tax synergi cost save year
peak ep accret signific ocf reduc debt support grow
dividend pursu mid-lat stage pipelin asset cost
capit within first full year
synergi cost save expect result reduc overlap
resourc billion drive effici sg includ sale market
central support function cost million elimin
redund manufactur suppli chain leverag procur spend
million
expect gener signific annual oper cash flow support
debt reduct target billion end de-lever
also enabl continu commit better credit
rate continu dividend growth
financi project relat transact
accret first full year peak
synergi least year three synergi divid follow sg
financ support fulli underwritten bridg facil
de-lever debt reduct
net debt/ebitda target near term improv subsequ year
four key therapeut area less depend humira
new four prioriti diseas area immunolog hematology-oncolog
medic aesthet neurosci three largest market franchis base
sale humira revenu imbruvica total mavyret
total
top five drug evolut estim top five drug drug
percentag pro forma revenu follow humira imbruvica
mavyret skyrizi venclexta estim top five
drug drug percentag revenu follow skyrizi
imbruvica skyrizi vencelxta humira vraylar
exhibit exhibit
exhibit top drug forma global revenu
exhibit top drug forma global revenu
exhibit market product key nme pipelin candid phase yellow shade indic product came allergan
exhibit ms estim stand-alon ww sale
exhibit ms estim allergan ww sale
exhibit ms estim stand-alon ww sale
exhibit ms estim allergan ww sale
exhibit allergan payer mix global revenu
jan announc creation new busi allergan aesthet
announc follow leadership combin compani
execut bio detail
chairman board chief execut offic richard gonzal
senior vice presid presid global allergan aesthet carri
incom ep break compani two compon abbvi
ex-humira humira project compound-annual-growth-rate revenu growth ex-humira
global humira project ex-humira sale grow
humira sale declin
model reflect bottom revenu earn specif
sale oper margin ep expect
oper margin begin rise return revenu growth
flow project project oper cash flow
one-tim cash charg merger cost note abbvi
state expect achiev annual merger save year post
close assum annual pro forma dividend assum total
share outstand project annual capital-expenditure
pro forma free cash flow ocf less capital-expenditure less dividend assumpt
balanc sheet leverag project assum pro forma total debt
net debt close acquisit allergan estim net debt
ebitda engag next
three year assum net debt end repres
ebitda
gentlest patent cliff post-humira
exhibit revenu exposur gener
biosimilar competit
smallest patent cliff overcom circa among us major
pharma like peer mid-lat decad outlook cloud patent loss
pipelin question howev silver line estim
revenu risk gener biosimilar competit
smallest five compani
three biggest product risk humira imbruvica vraylar
sale risk
humira biosimilar set enter market start januari
estim humira account total revenu yoy
sale growth
model humira constitut total sale
imbruvica gener could launch model imbruvica
revenu total grow total
vraylar could face gener competit us model vraylar
sale total grow total
exhibit patent cliff order revenu exposur grey row small molecul white
row biolog complex formul gener face less steep declin
sale sale patent expir
ex-u biosim enter late
us estimate assum gx sinc intestitin pump
 assum gx sinc implant
certain humira biosimilar competitor like design interchang
us fda sandoz demonstr humira biosimilar hyrimoz clinic
meaning differ efficaci safeti rheumatoid arthriti compar
humira phase admyra interchang studi boehring ingelheim bi also
conduct phase interchang trial voltaire-x biosimilar cyltezo
model global humira sale declin
model us humira sale grow declin rapidli
expect launch first biosimilar humira us jan eight
compani settlement allow launch june dec
model sever us eros ex-u biosimilar eros seen date sinc us
humira could face nine biosimilar includ januari other
june-dec assum steeper eros humira remicad enbrel
experienc ex-u recent year project us humira declin
ex-u humira declin project declin
note ex-u humira erod due biosimilar
pressur europ initi face addit countri exposur read
regard remicad enbrel
remicad ex-u declin yoy sinc biosimilar enter enbrel ex-
us mostli declin mid-teen yoy exhibit
exhibit remicad ex-u sale yoy growth first biosimilar launch februari
exhibit enbrel ex-u sale yoy growth first biosimilar launch januari
newli launch immunolog product jak rinvoq skyrizi
strong start mission gonzalez replac portion
humira sale new indic launch potenti next year
import upsid driver
model global skyrizi rinvoq sale increas
vs manag project skyrizi
rinvoq launch strongli despit entrench competit exhibit
exhibit estim skyrizi rinvoq compris total revenu
increas reach yoy estim
asid recent skyrizi script
trend impact stay-at-hom order new patient start
mainli administ physician offic expect return growth
order lift notabl manag rais guidanc skyrizi
may
exhibit launch tremfya skyrizi ilumya stelara launch script
unfortun tremfya skyrizi ilumya approv plaqu psoriasi tremfya dose
everi month wherea skyrizi ilumya dose everi month note skyrizi slow
recent due stay-at-hom order
tremfya skyrizi script restrict unreli tremfya launch skyrizi launch ilumya launch
xeljanz launch week olumi launch week rinvoq launch week
bullish skyrizi rinvoq replac well half peak humira global
sale two product combin indic includ
humira major indic plu one indic humira atop
dermat accord manag call skyrizi alreadi captur
in-play market share sinc launch apr rinvoq gain
in-play share rheumatoid arthriti sinc launch aug
project skyrizi sale rinvoq sale skyrizi
expect six approv includ psoriasi approv apr
rinvoq expect seven approv includ rheumatoid arthriti
approv aug exhibit histor context
manag project skyrizi across four indic pso cd uc
rinvoq across six indic combin
regulatori submiss rivoq psoriat arthriti atop dermat
ankylos spondyl skyrizi psoriat arthriti crohn diseas
data readout rinvoq atop dermat phase readout mid skyrizi
psoriat arthriti crohn diseas phase readout
exhibit skyrizi rinvoq expect approv time indic manag estim sale
compani estim sale skyrizi rinvoq
expect year approv
one risk immunolog increasingli competit market multipl drug
class approv develop seek win share compet
skyrizi rinvoq across multipl indic within jak inhibitor rinvoq
like compet lilli olumi xeljanz abrocitinib gilead
filgotinib across six indic within inhibitor skyrizi like
compet lilli mirikizumab sun pharma ilumya tremfya across five
indic exhibit
exhibit immunolog therapeut landscap oral/top drug phase approv diseas area
topic cream formul test mild-to-moder atop dermat plaqu psoriasi eucrisa topic cream approv mild-to-moder atop dermat
note gray cell indic diseas area either fail move phase sinc strateg updat green cell indic approv diseas area red cell indic on-going clinic trial orang cell indic regulatori review
expect approv
exhibit immunolog therapeut landscap inject phase approv diseas area
note gray cell indic diseas area either fail move phase sinc strateg updat green cell indic approv diseas area red cell indic on-going clinic trial orang cell indic regulatori review
discuss
readout
psoriasi cross-trial trial comparison
psoriasi market crowd multipl mechan includ
two approv plaqu psoriasi sun pharma ilumya
tremfya stelara addit lilli mirikizumab two phase trial
announc vs placebo met co-
primari key secondari endpoint vs cosentyx expect
complet later three approv plaqu psoriasislilli
taltz novarti cosentyx valeant bauch siliq addit ucb announc
posit toplin bimekizumab phase trialsb vivid vs stelara
readi vs placebo sure vs humira late includ show
superior stelara humira fourth phase trial radiant vs
cosentyx expect readout end expect detail result
bimekizumab studi regulatori submiss summer
skyrizi demonstr compel efficaci psoriasi cross-trial comparison skyrizi
efficaci better humira otezla appear
compar lilli taltz exhibit
skyrizi show better efficaci compar nv cosentyx phase trial
week skyrizi met primari pasi secondari endpoint includ
pasi pasi spga vs cosentyx moder sever plaqu psoriasi
specif skyrizi patient achiev pasi vs cosentyx week
also achiev non-inferior cosentyx week skyrizi patient
achiev pasi vs cosentyx new safeti signal observ
trial rate seriou skyrizi vs cosentyx lead
discontinu skyrizi cosentyx
dermatologist expert view agent similarli effect
psoriasi accord dermatologist interview april see agent
faster skin clearanc one two week higher
respond rate base data approv therapi regardless often insur
coverag determin choic therapi impact clinic profil unclear
among expert see taltz better efficaci data cosentyx
better payer access among view tremfya skyrizi similar
much effect sun ilumya addit expert see potenti competitor
bimekizumab excit candid psoriasi psoriat arthriti
potenti competitor includ oral drug bristol
expect complet date juli
understand expect data earli trial
includ otezla activ compar obviou concern
safeti signal observ phase phase expect readout
dermatolog expert interview believ
excit agent oral drug note show
similar efficaci humira stelara week rel benign manag
side effect headach infect acn asid
topic cream formul phase poc trial mild-to-moder
psoriasi trial expect readout
exhibit cross-trial comparison plaqu psoriasi oral data week oral otezla data week oral xeljanz week
inj humira data week inj taltz data week inj skyrizi data week note pfizer abandon xeljanz psoriasi
awar jak develop psoriasi
pool
rinvoq ph efficaci appear compar better dupix ph
look forward rinvoq head-to-head trial result vs dupix earli
could potenti chang treatment landscap head trial
compar rinvoq vs sanofi/regeneron dupix patient moder
sever atop dermat primari endpoint easi week estim primari
complet septemb sanofi cover mark purcel regeneron
cover matthew harrison
rinvoq show highli compel efficaci phase compar cross-trial
dupix phase compar placebo-adjust result rinvoq phase
cross-trial dupix phase week mean chang easi
rinvoq mg vs dupix easi vs
easi vs iga respons
vs pruritu nr improv vs
exhibit
rinvoq higher rate upper respiratori tract infect compar placebo
though side effect appear benign rate infect arm
vs placebo arm common rinvoq atop dermat
worsen acn seriou rel uncommon appear
increas higher dose occur patient mg arm vs
patient placebo case venou thromboembol dermatolog
expert interview said rinvoq seem efficaci dupix cross-trial
side effect profil bad atop dermat patient
competitor jak inhibitor abrocitinib mg show superior itch
reduct week compar dupix primari endpoint efficaci
discuss rel placebo posit top-lin result jade compar show
abrocitinib reduc itch secondari endpoint compar
dupix week dose abrocitinib itch reduct numer
better statist signific compar dupix detail
present time need see detail order compar
abrocitinib dupix primari efficaci endpoint note rel itch relief
abrocitinib secondari endpoint formal compar dupix week
primari endpoint iga easi week plan
regulatori file fda later
abrocitinib safeti could offset factor rel dupix abrocitinib
oral jak inhibitor dupix twice-monthli inject receptor
alpha antagonist jade compar abrocitinib group experienc
compar dupix similar rate seriou abro
vs dupi lead discontinu abro vs dupi safeti
data present releas plan scrutin abrocitinib rate nausea
immunosuppress abrocitinib jade trial present last year
abrocitinib mg safeti issu includ rate nausea median durat
day decreas platelet count hemorrhag event mg dose
previous disclos abrocitinib data show greater efficaci side effect
mg dose mg dose higher dose abrocitinib mg qd previous
show compel efficaci phase cross-trial dupix mg
mg abrocitinib like associ safeti issu dermatolog
expert note abrocitinib dose effect headach gi side
effect may issu look forward result includ rate
immunosuppress nausea exhibit
exhibit atop dermat cross-trial comparison placebo-adjust efficaci result
mean chang easi
iga
ibd opportun competit landscap
ibd repres larg market opportun us humira sale
ibd cd uc exhibit us
humira share market cd uc exhibit
exhibit humira sale indic
exhibit us humira market share
skyrizi rinvoq investig ulcer coliti crohn diseas
late market appear without differenti
product profil ulcer coliti rinvoq phase u-accomplish readout
expect skyrizi phase primari complet sept phase
expect readout crohn diseas rinvoq phase expect primari
complet june skyrizi phase motiv expect primari complet
march rel competit skyrizi could potenti disadvantag
inject rinvoq black box warn exhibit exhibit ulcer
coliti crohn diseas trial outcom comparison see publish note
ozanimod compel novel oral ibd ibd learn hc insight
day addit background inform
exhibit comparison uc trial outcom ozanimod etrasimod mirikizumab rinvoq approv therapi
moder sever uc
morgan stanley research compani present
morgan stanley research compani present
exhibit comparison crohn trial outcom ozanimod filgotinib rinvoq skyrizi approv therapi
moder sever crohn
imbruvica heme-onc product
imbruvica second largest product behind humira
model revenu vs manag peak revenu project
us sale ex-u profit split imbruvica first-in-class btk
inhibitor establish standard care cll largest indic
frontlin relapsed/refractori set well high-risk patient
us imbruvica sale cll exhibit
recent year focus penetr frontlin market
strengthen clinic data via combin therapi includ combin
obinutuzumab ginzyva approv januari
combin rituxan approv april
cll remain lead indic key growth driver imbruvica despit
potenti competit approxim half imbruvica revenu expect come
cll imbruvica fail dlbcl multipl myeloma pancreat cancer sinc
last strateg updat competit current expect new btk
inhibitor astrazeneca calquenc beigen brukinsa signific threat
imbruvica given amount clinic data gener year
physician familiar product new player like compet
newli diagnos patient patient fail earlier treatment manag state
earn call imbruvica use half cll patient
patient captur newli diagnos patient set new
player need compet venclexta inhibitor plan
watch potenti btk competitor astrazeneca beigen trial previously-
treat cll expect readout see detail chronic lymphocyt
exhibit us imbruvica sale indic
venclexta inhibitor complement imbruvica cll
potenti move biomarker-specif multipl myeloma
model global sale vs manag project
note competitor need compet venclexta set
approxim venclexta sale expect come cll near term
accord venclexta captur new patient share
set three month post-approv venclexta
investig multipl myeloma mutat popul canova trial
common transloc report frequenc
move forward dlbcl follicular lymphoma trial phase today
asid run phase imbruvica venclexta combo vs imbruvica
relapsed/refractori mantl cell lymphoma sympatico expect readout
exhibit imbruvica venclexta hematology-oncolog landscap phase trial approv indic
gray cell indic diseas area either fail move phase sinc strateg updat green cell indic approv diseas area red cell indic on-going clinic trial
competitor head-to-head trial vs imbruvica expect read
azn calquenc beigen brukinsa second-gener btk inhibitor seek
compet imbruvica potenti less side effect atrial fibril
hypertens compar better efficaci known major side effect imbruvica
cardiac-rel advers event includ atrial fibril hypertens major
hemorrhag calquenc brukinsa develop hope similar
possibl improv efficaci reduc toxic compar imbruvica
astrazeneca/acerta run elev cll r/r compar calquenc
acalabrutinib vs imbruvica ibrutinib previous treat high risk cll
clinicaltri gov indic trial enrol patient estim primari
final complet march primari endpoint progression-fre surviv
secondari endpoint includ overal surviv atrial fibril advers
exhibit imbruvica vs calquenc cross-trial comparison cll
median follow month
cross btk monotherapi
interest
atrial fibril grade
hypertens grade
beigen run alpin compar brukinsa zanubrutinib vs imbruvica
previous treat cll alpin enrol patient estim primari
complet novemb primari endpoint overal respons rate
first assess non-inferior superior secondari endpoint includ
os brukinsa approv treatment
notabl waldenstrm macroglobulinemia wm brukinsa show trend
superior vs imbruvica aspen trial primari endpoint complet
respons cr good partial respons vgpr rate brukinsa vs
imbruvica rate grade seriou similar
two drug brukinsa lower rate fatal ae lead treatment
discontinu ae lead dose reduct atrial fibril major hemorrhag
diarrhea hypertens
exhibit beigen brukinsa vs imbruvica phase aspen data wm
descript bleed grade bleed grade
longer term await clinic trial readout non-coval btk inhibitor
lilli earli stage competit risk seem limit
time expect imbruvica continu lead market number
patient cystein mutat lose respons btk inhibitor small
initi indic test
iqvia total script market share indic imbruvica market share decreas
slowli low mid januari
exhibit trx market share trend indic limit impact azn competitor calquenc note
key allergan growth driver neurosci includ botox
aesthet neuro botox aesthet gener annual revenu
stand-alone stand-alone
respect neuro incl botox therapeut mainli consist vraylar botox
viibryd/fetzima oral cgrp pipelin product aesthet segment
consist botox cosmet juvederm alloderm coolsculpt breast implant
estim total aesthet revenu grow compound-annual-growth-rate
medic aesthet durabl cash pay busi
could potenti benefit commerci capabl infrastructur
current model key segment growth driver botox cosmet juvederm grow
compound-annual-growth-rate respect apart botox
juvederm segment also includ emerg bodi contour treatment
coolsculpt model grow
compound-annual-growth-rate overal allergan lead aesthet product bundl help aesthet
segment deliv durabl growth competit under-penetr market
neuro botox
expect grow combin sale
combin sale compound-annual-growth-rate vraylar botox therapeut
signific growth driver come year potenti peak sale
estim vraylar account
respect combin abbv/ revenu addit two
competit oral cgrp atogep migrain prophylaxi ubrogep acut
migrain approv dec launch expect shortli substanti
contribut growth come year current model ubrelvi ubrogep
sale atogep risk-adjust sale separ
note manag emphas neuro one key growth area
complement capabl alreadi market duodopa
advanc parkinson diseas ph
exhibit aesthet neurosci franchis total combin revenu
total revenu
neurosci includ botox vraylar viibryd ubrelvi atogep
key allergan product rel resili lockdown
linzess pro-forma sale vraylar pro-forma sale
trend moder slightli recent week exhibit exhibit
exhibit linzess strength weekli yoy growth trend
exhibit vraylar absolut yoy trend
exhibit migrain weekli total cgrp includ aimovig ajovi emgal ubrelvi
thin late-stag pipelin drive low investor expect sentiment
could improv early-stag pipelin advanc note sever
proof-of-concept readout next year
biodegrad sustain releas implant lumigan
pdufa
pdufa ema action
ph migrain prophylaxi trial expect complet
phase success ovarian velia brca breast
cancer file expect
approv expect
duopa ph data readout expect
commerci anticip
ph r/r myelofibrosi start ph r/r
myelofibrosi prelim data present
submiss expect potenti
acceler approv
exhibit early-stage/proof-of-concept pipelin order next event time
anti-tnf/steroid show zero system side effect ph
ph data expect
ph data expect ph sjgren syndrom
expect begin
ph psoriasi readout expect prim compl
ph cmet solid tumor readout expect
ph r/r solid tumor monotherapi data
combo data
ph rrm progress ms
primari complet
ph earli alzheim trial interim readout end
trial conclus
expect ra ph failur announc
ph cystic fibrosi homozyg mutat
readout expect prim compl feb
could transform efficaci long-term safeti need
demonstr expect ph proof concept data may-jun
head michael severino highlight potenti
transform call antibody-drug conjug
consist anti-tnf antibodi steroid idea abl deliv
drug case steroid specif target case immun cell via
antibodi case tnf accompani system side effect
technolog success could platform would broad applic
phase poc data iv expect soon call proof-of-
concept phase trial ra expect read soon trial evalu abbv-
anoth tnf-steroid dose iv humira dose
subcutan primari endpoint week estim primari complet
phase studi sq show impact serum cortisol level abbv-
dose subcutan mg mg healthi volunt show
impact serum cortisol level similar placebo day post-dos contrast
prednison mg depress serum cortisol level day post-dos exhibit
exhibit deliv steroid immun cell target
manner theoret would demonstr durabl inhibit
inflamm system side effect
phase data encourag await ph proof
efficaci long-term safeti understand
seen flatlin diseas anim model hope
phase poc show efficaci least compar humira
better safeti addit phase data use
subcutan formul phase ra trial dose iv
await clariti rout administr
exhibit dose subcutan phase show chang serum cortisol
alzheim high-risk high-reward call option given histor biopharma
enthusiasm potenti alzheim option could potenti grow street
yet focu alzheim option even though compani
second lever us large-cap pharma compani alzheim option
behind lilli see wildcard readout tau phase result
current develop three candid
proof concept result like human
antibodi target aggreg extracellular tau differ anti-
tau antibodi requir uptak neuron fail phase
trial progress supranuclear palsi psp juli believ read-
phase earli alzheim trial current on-going would minim
given differ type tau fibril character psp alzheim howev
report suggest would block propag misfold tau
target n-terminu tau rather mid-region primari endpoint
clinic dementia rate box cdr-sb week trial
three treatment arm one placebo arm patient meet
nation institut age alzheim associ nia-aa clinic criteria
mild cognit impair probabl ad primari complet date april
proof concept result like profit split
ticker cover matthew harrison monoclon antibodi
intend enhanc activ trigger receptor express
myeloid thought promot improv cell migrat site
injuri improv cell surviv increas phagocytosi increas cell
prolifer hypothesi base rare genet variant
strongli associ increas risk develop alzheim howev
variant occur popul compar
unknown whether target could effect non-vari
phase trial invok estim final complet date march primari
complet dec trial enrol subject healthi adult
patient mild-moder alzheim primari endpoint safeti
toler day volunt data present ctad last
decemb show dose-depend reduct csf solubl elev
microgli activ support proof-of-target mechan phase proof-
of-concept studi expect start
ph safeti data expect profit split
monoclon antibodi target sialic acid bind ig-lik lectin siglec
microgli transmembran receptor believ interact genet
mutat siglec receptor shown increas risk
develop alzheim diseas inhibit benefici activ brain
immun system phase trial intercept estim primari
complet date april trial enrol subject healthi adult
patient mild-moder alzheim primari endpoint safeti
toler day
co-develop term
agreement octob grant exclus option global
develop commerci two program program
respons design execut phase phase studi leverag
alector in-hous expertis run clinic trial alzheim diseas follow
exercis option program respons certain develop
activ global commerci term agreement includ initi
up-front payment cash equiti exercis option
either program program elig addit option exercis
mileston payment total follow exercis option
share develop cost split global profit
equal market approv
list pipelin asset
exhibit pipelin
skyrizi humira
pdufa uterin fibroid submit jul
phase readout atop dermat measur prim compl apr
toplin octdec radiant cosentyx end submiss expect summer
treatment hospit pt reduc pulmonari failur risk inspir prim compl juli
phase readout roch semorinemab anti-tau prodromal-earli alzheim tauriel prim
phase readout crohn induct motiv psoriat arthriti
submiss expect
abrocitinib jak phase dupix jade compar ad posit top-lin await
detail fill later
phase readout cgvhd integr prim compl jul submiss expect
phase data cll/sll captiv readout expect submiss expect prim compl
sep prelim data present
phase interim readout earli alzhim cdr-sb prim endpt prim compl apr
phase data ra expect prim compl dec
phase data psoriasi prim compl sept
fda action younger adult cll/sll phase ecog vs fcr submit
phase data ulcer coliti expect begin sjogren syndrom
phase data atop dermat ulcer coliti hidraden suppurativa hs
phase cmet solid tumor readout expect
boehring ingelheim humira biosimilar bi interchang trial readout voltaire-x complet
phase solid tumor readout monotherapi expect combo therapi
phase readout atop dermat vs dupix head prim compl sep
phase readout roch semorinemab anti-tau moder alzheim lauriet prim endpt/compl
phase cystic fibrosi homozyg mutat readout expect prim compl feb
ph rrm progress ms readout expect
phase solid heme tumor proof concept data expect
phase continu subq parkinson pivot data expect primary/studi compl
phase polycyst ovari syndrom pco readout expect
ad indic approv expect file expect
phase data sle ra poc failur announc
azn/acerta phase r/r cll trial acalabrutinib vs imbruvica elev cll r/r prim compl jun final
beigen phase r/r cll trial zanubrutinib vs imbruvica alpin prim compl feb final compl oct
phase readout multipl myeloma mutat canova prim compl jan
phase readout r/r fl mzl selen readout expect
phase readout vs g-clb cll glow readout expect
imbruvica bendamustine/rituxan r-
venclexta imbruvica and/or phase readout vs fcr/br cll without tp mutat readout expect
phase readout r/r mcl sympatico readout submiss expect
phase readout mantl cell lymphoma shine readout expect
phase r/r mm vs pomalyst canova data expect
phase earli alzheim prim endpt cdr-sb prim compl apr
beigen phase waldenstrm macroglobulinemia trial zanubrutinib vs imbruvica aspen prim/fin compl
jun fail meet superior dec total data encour
approv ovarian cancer brca breast cancer submiss
approv cgvhd expect
phase cmet nsclc primari complet oct
phase r/r myelofibrosi potenti data readout phase trial start
myelofibrosi approv expect
parkinson commerci expect
crohn approv expect submiss plan
atop dermat approv expect
uc crohn diseas gca axspa approv expect
uc hs approv expect
price
price
price
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
exhibit trade mean histor mean
exhibit incom statement margin analysi valuat
sg sale
 sale
exhibit balanc sheet statement
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
